Company Name
KEYZELL HOLDING, SL
Activity
Biotech
CIF
B01686351
Sector
BIOTECH
Address
AVDA DE LA AERONÁUTICA, 10 7-3 - SEVILLA
EPM Joining Date
18/03/2024
Creation Date
01/06/2020
Founders JOSE DEL CORRAL SÁNCHEZ, JUAN ANTONIO SOLANES MASCARELL, MIGUEL VILAPLANA SERRANO, JESÚS ORTIGUEIRA SÁNCHEZ Y DR NABIL HAJJI.
Auditor
BDO
Investors email contact
INFO@KEYZELL.COM
Presenting Partner
Foro Capital Pymes
Company profile
KeyZell, is a company that has combined biotechnology with mathematics, to develop new solutions against the fight against cancer.
On the Road to BME Growth
Relevant data
| (thousand of Euros) | 2022 | 2023 | 2024* | 2025* |
|---|---|---|---|---|
| Net worth | 861 | 1.493 | - | - |
| Net business turnover | 00 | 00 | - | - |
| Financial debt | 31 | 00 | - | - |
| Ebitda | -260 | -435 | 1.842 | 58.130 |
| Net Profit | -265 | -254 | 1.842 | 58.130 |
| Average number of employees | - | 02 | - | - |
| * Proyection | ||||
Investment Rounds
| Date | Status | Amount | Minimum Ticket |
|---|---|---|---|
| 19-03-2024 | Open | 5.000.000 | 100000,00 |
Business Model
KeyZell is a biopharmaceutical and deep-tech company that uses a cutting-edge technological approach to innovations in biomedical sciences to transform the R&D of new drugs in a holistic way and the development of artificial intelligence tools for the fight against cancer.
Competitive advantage
There is no treatment that has achieved the results obtained by LZ-167 in the previous phases. In 2023 KeyZell conducted a Compassionate Use clinical trial in a 53-year-old patient with metastatic osteosarcoma in stage IV, achieving excellent results with a reduction of more than 30% in all tumours.
